PMID- 23531221
OWN - NLM
STAT- MEDLINE
DCOM- 20131108
LR  - 20220317
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 20
IP  - 18
DP  - 2013
TI  - Insulin secretion and interleukin-1beta dependent mechanisms in human diabetes 
      remission after metabolic surgery.
PG  - 2374-88
AB  - To compare endocrine, metabolic, and inflammatory changes induced by gastric 
      bypass (GB) and sleeve gastrectomy (SG) in patients with type 2 diabetes mellitus 
      (T2DM), and to investigate the mechanisms of success after metabolic surgery. 
      Sixteen GB and 16 SG patients were followed up before and at 1 year after 
      surgery. The 75-g oral glucose tolerance test (OGTT) was performed before and 
      after surgery. Glucose homeostasis, serum interleukin-1beta, plasma gut hormones and 
      adipokines, and the United Kingdom Prospective Diabetes Study (UKPDS) ten-year 
      cardiovascular risks were evaluated. The diabetes remission rate was 
      significantly higher in GB than SG. Changes in the area under the curve (AUC) for 
      glucose were greater in those with complete and partial remission after GB and 
      remitters after SG than non-remitters after SG, whereas changes in AUC for 
      C-peptide were higher in complete and partial remitters after GB than 
      non-remitters after SG. Insulinogenic index was enhanced and serum interleukin-1beta 
      was reduced in complete remitters after GB and remitters after SG. Logistic 
      regression analysis confirmed that insulinogenic index and interleukin-1beta, not 
      insulin resistance, were the factors determining the success of diabetes 
      remission after metabolic surgeries. GB and SG significantly reduced the ten-year 
      risk of coronary heart disease and fatal coronary heart disease in T2DM patients 
      after surgery, while GB had the additional benefit of reduced stroke risk. Human 
      diabetes remission after metabolic surgery is through insulin secretion and 
      interleukin-1beta dependent mechanisms. GB is superior to SG in cardiocerebral risk 
      reduction in Asian non-morbidly obese, not well-controlled T2DM patients.
FAU - Chen, Chih-Yen
AU  - Chen CY
AD  - Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, 
      Taiwan. chency@vghtpe.gov.tw
FAU - Lee, Wei-Jei
AU  - Lee WJ
FAU - Asakawa, A
AU  - Asakawa A
FAU - Fujitsuka, N
AU  - Fujitsuka N
FAU - Chong, Keong
AU  - Chong K
FAU - Chen, Shu-Chun
AU  - Chen SC
FAU - Lee, Shou-Dong
AU  - Lee SD
FAU - Inui, A
AU  - Inui A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Adipokines)
RN  - 0 (Cytokines)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-1beta)
SB  - IM
MH  - Adipokines/blood
MH  - Adult
MH  - Cardiovascular Diseases/etiology
MH  - Cytokines/blood
MH  - Diabetes Mellitus, Type 2/*blood/complications/metabolism/*surgery
MH  - Female
MH  - *Gastrectomy
MH  - *Gastric Bypass
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/blood/*metabolism
MH  - Interleukin-1beta/*blood/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 2013/03/28 06:00
MHDA- 2013/11/10 06:00
CRDT- 2013/03/28 06:00
PHST- 2013/01/04 00:00 [received]
PHST- 2013/02/22 00:00 [revised]
PHST- 2013/03/12 00:00 [accepted]
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2013/11/10 06:00 [medline]
AID - CMC-EPUB-20130315-10 [pii]
AID - 10.2174/0929867311320180008 [doi]
PST - ppublish
SO  - Curr Med Chem. 2013;20(18):2374-88. doi: 10.2174/0929867311320180008.